Correction Notice on a Study About Lung Cancer Drug Costs

The Italian research team has released an update to their earlier work that examined how affordable the drug osimertinib is for patients with a specific type of lung cancer. The original paper, published in the December 2025 issue of ESMO Real World Data and Digital Oncology, used real‑world patient records to analyze cost‑effectiveness. In the update, the authors clarify a detail that was overlooked in their first report.They point out that the digital method they used to pull information from electronic health records had a small error in how it counted certain treatment costs. The correction does not change the overall message that osimertinib can be a cost‑efficient option, but it ensures that future readers have the accurate numbers. The corrected version can be found by following the DOI 10. 1016/j. esmorw. 2025. 100198. This kind of transparency is common in scientific publishing, where researchers publish brief notes to fix mistakes or clarify methods. It helps keep the evidence base reliable and lets clinicians make better decisions for patients.